John Fung to Tacrolimus
This is a "connection" page, showing publications John Fung has written about Tacrolimus.
Connection Strength
9.390
-
Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. Transplantation. 2017 Feb; 101(2):341-349.
Score: 0.510
-
Predicting immunosuppressant dosing in the early postoperative period with noninvasive indocyanine green elimination following orthotopic liver transplantation. Liver Transpl. 2008 Jan; 14(1):46-52.
Score: 0.271
-
Long-term outcome of adding mycophenolate mofetil to tacrolimus for nephrotoxicity following liver transplantation. Transplantation. 2005 Sep 27; 80(6):859-64.
Score: 0.232
-
Tacrolimus and transplantation: a decade in review. Transplantation. 2004 May 15; 77(9 Suppl):S41-3.
Score: 0.211
-
Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. Transplantation. 2004 Mar 27; 77(6):897-902.
Score: 0.209
-
Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center's experience update at 13 years. Transplantation. 2003 Sep 15; 76(5):827-32.
Score: 0.202
-
Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transpl. 2003 Sep; 9(9):954-60.
Score: 0.201
-
Conversion from tacrolimus to cyclosporine--a based immunosuppression following liver transplantation. Exp Clin Transplant. 2003 Jun; 1(1):48-55.
Score: 0.198
-
Tolerogenic immunosuppression for organ transplantation. Lancet. 2003 May 03; 361(9368):1502-10.
Score: 0.196
-
The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transpl. 2002 Sep; 8(9):841-5.
Score: 0.188
-
Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. Transplant Proc. 2002 Aug; 34(5):1540-1.
Score: 0.186
-
A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation. 2001 Sep 27; 72(6):1091-7.
Score: 0.176
-
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years. Liver Transpl. 2001 Jul; 7(7):623-30.
Score: 0.173
-
Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. Transplantation. 2001 Apr 27; 71(8):1102-6.
Score: 0.171
-
Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol. 2001 Mar; 41(3):268-76.
Score: 0.169
-
Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. Transplant Proc. 2001 Feb-Mar; 33(1-2):1342-4.
Score: 0.168
-
Renal retransplantation in elderly recipients under tacrolimus-based immunosuppression. Transplant Proc. 2000 May; 32(3):663-4.
Score: 0.160
-
Outcome of kidney transplantation under tacrolimus-based immunosuppression in elderly patients. J Transpl Coord. 1999 Jun; 9(2):101-3.
Score: 0.150
-
Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg. 1999 Mar; 5(2):144-50.
Score: 0.147
-
A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation. 1998 Nov 27; 66(10):1395-8.
Score: 0.145
-
Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg. 1998 Nov; 4(6):448-54.
Score: 0.144
-
Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis. 1998 Jun; 31(6 Suppl 1):S7-14.
Score: 0.140
-
Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. Transplant Proc. 1998 Jun; 30(4):1403-4.
Score: 0.140
-
Kaposi's sarcoma in liver transplant recipients on FK506. Transplantation. 1998 Apr 27; 65(8):1140.
Score: 0.139
-
The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg. 1996 Aug; 183(2):117-25.
Score: 0.123
-
FK506 in solid organ transplantation. Ther Drug Monit. 1995 Dec; 17(6):592-5.
Score: 0.117
-
Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. Transplantation. 2015 Jul; 99(7):1455-62.
Score: 0.114
-
FK 506 in solid organ transplantation. Transplant Proc. 1994 Oct; 26(5):3017-20.
Score: 0.108
-
FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. Transplant Proc. 1994 Jun; 26(3):1211.
Score: 0.106
-
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation. 1994 Mar 27; 57(6):860-5.
Score: 0.105
-
De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant. 2014 Feb; 14(2):356-66.
Score: 0.103
-
Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. Autoimmunity. 1994; 19(2):89-98.
Score: 0.103
-
Retransplantation of liver: a comparison of FK 506- and cyclosporine-treated patients. Transplant Proc. 1991 Dec; 23(6):3026-8.
Score: 0.089
-
Adverse effects associated with the use of FK 506. Transplant Proc. 1991 Dec; 23(6):3105-8.
Score: 0.089
-
The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. Transplant Proc. 1991 Dec; 23(6):3234-5.
Score: 0.089
-
Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. Transplant Proc. 1991 Dec; 23(6):3238-9.
Score: 0.089
-
Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. Transplantation. 2006 Dec 27; 82(12):1621-4.
Score: 0.063
-
Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. Transplantation. 2006 Dec 27; 82(12):1649-52.
Score: 0.063
-
Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation. 2004 Dec 15; 78(11):1683-8.
Score: 0.055
-
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation. 2004 Oct 15; 78(7):966-71.
Score: 0.054
-
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg. 2003 Oct; 238(4):520-5; discussion 525-7.
Score: 0.051
-
The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. Transplantation. 2003 Apr 15; 75(7):1020-5.
Score: 0.049
-
A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. Transplant Proc. 2002 Aug; 34(5):1651-2.
Score: 0.047
-
Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimus. Transplant Proc. 2002 Aug; 34(5):1968-9.
Score: 0.047
-
A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl. 2002 Jan; 8(1):40-6.
Score: 0.045
-
Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant. 2001 Oct; 5(5):359-64.
Score: 0.044
-
Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation. 2001 Sep 15; 72(5):851-5.
Score: 0.044
-
Quantitation of immunosuppression by tacrolimus using flow cytometric analysis of interleukin-2 and interferon-gamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther Drug Monit. 2001 Aug; 23(4):354-62.
Score: 0.043
-
Induction Therapy With Antithymocyte Globulin and Delayed Calcineurin Inhibitor Initiation for Renal Protection in Liver Transplantation: A Multicenter Randomized Controlled Phase II-B Trial. Transplantation. 2022 05 01; 106(5):997-1003.
Score: 0.043
-
Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. Transplantation. 2001 Jan 27; 71(2):267-71.
Score: 0.042
-
Evidence of microchimerism after pretransplant blood transfusion and FK 506 in liver xenograft. Transplant Proc. 2000 Dec; 32(8):2710-2.
Score: 0.042
-
Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 2000 Sep 15; 70(5):760-4.
Score: 0.041
-
Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation. 2000 Jun 15; 69(11):2330-6.
Score: 0.040
-
Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. Transplantation. 2000 Jan 27; 69(2):265-71.
Score: 0.039
-
Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 1999 Dec 27; 68(12):1851-4.
Score: 0.039
-
An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation. 1999 Sep 15; 68(5):650-5.
Score: 0.038
-
Posttransplant diabetes in pediatric recipients on tacrolimus. Transplantation. 1999 Mar 15; 67(5):771.
Score: 0.037
-
A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation. 1999 Feb 15; 67(3):411-5.
Score: 0.037
-
Immunosuppressive therapy. Surg Clin North Am. 1999 Feb; 79(1):59-76.
Score: 0.037
-
Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. Transplant Proc. 1999 Feb-Mar; 31(1-2):646-7.
Score: 0.037
-
Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions. Transplant Proc. 1999 Feb-Mar; 31(1-2):700-1.
Score: 0.037
-
A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. Transplant Proc. 1999 Feb-Mar; 31(1-2):1134.
Score: 0.037
-
Long-term results of pancreas transplantation under tacrolius immunosuppression. Transplantation. 1999 Jan 27; 67(2):266-72.
Score: 0.037
-
Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation. 1999 Jan 27; 67(2):299-303.
Score: 0.037
-
A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol. 1998 Dec; 160(6 Pt 1):1982-5; discussion 1985-6.
Score: 0.036
-
Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation. 1998 Oct 27; 66(8):1047-52.
Score: 0.036
-
Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation. Transplant Proc. 1998 Jun; 30(4):1091-2.
Score: 0.035
-
Tacrolimus for rescue of refractory renal allograft rejection. Transplant Proc. 1998 Jun; 30(4):1257-60.
Score: 0.035
-
Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc. 1998 Jun; 30(4):1375-7.
Score: 0.035
-
Alopecia as a consequence of tacrolimus therapy. Transplantation. 1998 May 15; 65(9):1284.
Score: 0.035
-
Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. Transplant Proc. 1998 Mar; 30(2):521.
Score: 0.034
-
Outcome of kidney transplantation in African-Americans using tacrolimus. Transplant Proc. 1997 Dec; 29(8):3731-2.
Score: 0.034
-
Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. Transplant Proc. 1997 Sep; 29(6):2737-8.
Score: 0.033
-
Pregnancy after liver transplantation under tacrolimus. Transplantation. 1997 Aug 27; 64(4):559-65.
Score: 0.033
-
Five-year experience with tacrolimus rescue for renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):306.
Score: 0.032
-
Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):310.
Score: 0.032
-
Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus. Transplant Proc. 1997 Feb-Mar; 29(1-2):532-3.
Score: 0.032
-
High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in Mouse cardiac transplantation. Transplant Proc. 1997 Feb-Mar; 29(1-2):1081-2.
Score: 0.032
-
Tacrolimus rescue therapy for renal allograft rejection--five-year experience. Transplantation. 1997 Jan 27; 63(2):223-8.
Score: 0.032
-
"Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. Transplantation. 1996 Nov 15; 62(9):1242-6.
Score: 0.031
-
Tacrolimus rescue therapy for renal transplant rejection. Transplant Proc. 1996 Aug; 28(4):2119-20.
Score: 0.031
-
Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. Transplantation. 1996 Jun 27; 61(12):1730-5.
Score: 0.031
-
Effect of tacrolimus and splenectomy on engraftment and GVHD after bone marrow xenotransplantation in the reciprocal hamster to rat animal models. Transplant Proc. 1996 Apr; 28(2):736-7.
Score: 0.030
-
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet. 1995 Nov 18; 346(8986):1346-50.
Score: 0.029
-
Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. Transplantation. 1995 Sep 15; 60(5):512-4.
Score: 0.029
-
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation. 1995 Feb 27; 59(4):485-90.
Score: 0.028
-
One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. Transplant Proc. 1995 Feb; 27(1):1099-104.
Score: 0.028
-
Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens. Transplant Proc. 1995 Feb; 27(1):277.
Score: 0.028
-
A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. Transplant Proc. 1995 Feb; 27(1):814-7.
Score: 0.028
-
Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg. 1994 Sep; 220(3):297-308; discussion 308-9.
Score: 0.027
-
Pretransplant xenogeneic blood transfusion combined with FK 506 prolongs hamster-to-rat liver xenograft survival. Transplant Proc. 1994 Jun; 26(3):1208.
Score: 0.026
-
Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med. 1993 Oct 01; 119(7 Pt 1):595-8.
Score: 0.025
-
Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. Transplant Proc. 1993 Aug; 25(4):2433-4.
Score: 0.025
-
Serum cholesterol levels in African Americans after renal transplantation under FK 506 immunosuppression. Transplant Proc. 1993 Aug; 25(4):2435.
Score: 0.025
-
Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506. Transplant Proc. 1993 Jun; 25(3):2381-5.
Score: 0.025
-
Bronchiolitis obliterans organizing pneumonia in a BMT patient receiving FK506. Bone Marrow Transplant. 1993 Jun; 11(6):502.
Score: 0.025
-
FK 506 interaction with danazol. Lancet. 1993 May 22; 341(8856):1344-5.
Score: 0.025
-
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation. 1993 Mar; 55(3):659-61.
Score: 0.024
-
Two-year experience with FK 506 in pediatric patients. Transplant Proc. 1993 Feb; 25(1 Pt 1):619-21.
Score: 0.024
-
Long-term survival of heart and liver xenografts with splenectomy and FK 506. Transplant Proc. 1993 Feb; 25(1 Pt 1):647-8.
Score: 0.024
-
Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc. 1993 Feb; 25(1 Pt 1):669-72.
Score: 0.024
-
Intestinal transplantation in humans under FK 506. Transplant Proc. 1993 Feb; 25(1 Pt 2):1198-9.
Score: 0.024
-
Intestinal transplantation in composite visceral grafts or alone. Ann Surg. 1992 Sep; 216(3):223-33; discussion 233-4.
Score: 0.023
-
Low-dose of FK 506 and associated blood levels in allotransplantation of rat liver, heart, and skin. Transplant Proc. 1992 Aug; 24(4):1403-5.
Score: 0.023
-
Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol. 1992 Jun; 128(6):781-5.
Score: 0.023
-
Effect of FK 506 on human pancreatic islets following renal subcapsular transplantation in diabetic nude mice. Transplant Proc. 1992 Jun; 24(3):1042.
Score: 0.023
-
Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation. 1992 May; 53(5):1056-62.
Score: 0.023
-
Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. Am J Hosp Pharm. 1992 Jan; 49(1):119-22.
Score: 0.022
-
Strategy of FK 506 therapy in liver transplant patients: effect of graft function. Transplant Proc. 1991 Dec; 23(6):2771-4.
Score: 0.022
-
Interaction between FK 506 and cyclosporine in dogs. Transplant Proc. 1991 Dec; 23(6):2797-9.
Score: 0.022
-
The pharmacodynamics of pentobarbital following FK 506 therapy. Transplant Proc. 1991 Dec; 23(6):2800-1.
Score: 0.022
-
Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. Transplant Proc. 1991 Dec; 23(6):2873-4.
Score: 0.022
-
Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. Transplant Proc. 1991 Dec; 23(6):2957-8.
Score: 0.022
-
FK 506 versus cyclosporine in pediatric liver transplantation. Transplant Proc. 1991 Dec; 23(6):3010-5.
Score: 0.022
-
Liver transplantation of American veterans under FK 506 immunosuppression: a preliminary report. Transplant Proc. 1991 Dec; 23(6):3016-8.
Score: 0.022
-
Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. Transplant Proc. 1991 Dec; 23(6):3023-5.
Score: 0.022
-
CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. Transplant Proc. 1991 Dec; 23(6):3035-7.
Score: 0.022
-
Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. Transplant Proc. 1991 Dec; 23(6):3044-6.
Score: 0.022
-
Clinical small bowel or small bowel plus liver transplantation under FK 506. Transplant Proc. 1991 Dec; 23(6):3093-5.
Score: 0.022
-
Changes in renal function after liver transplantation under FK 506. Transplant Proc. 1991 Dec; 23(6):3143-5.
Score: 0.022
-
Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. Transplant Proc. 1991 Dec; 23(6):3148-9.
Score: 0.022
-
Neurologic complications of FK 506. Transplant Proc. 1991 Dec; 23(6):3175-8.
Score: 0.022
-
Human islet allotransplantation under FK 506. Transplant Proc. 1991 Dec; 23(6):3207.
Score: 0.022
-
FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc. 1991 Dec; 23(6):3225-7.
Score: 0.022
-
The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. Transplant Proc. 1991 Dec; 23(6):3232-3.
Score: 0.022
-
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc. 1991 Dec; 23(6):3269-71.
Score: 0.022
-
FK 506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc. 1991 Dec; 23(6):3322-4.
Score: 0.022
-
Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. Transplant Proc. 1991 Dec; 23(6):3325-7.
Score: 0.022
-
Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc. 1991 Dec; 23(6):3328-9.
Score: 0.022
-
Treatment of Cogan's syndrome with FK 506: a case report. Transplant Proc. 1991 Dec; 23(6):3347.
Score: 0.022
-
[Clinical experience with FK 506]. Presse Med. 1991 Nov 27; 20(40):1967-73.
Score: 0.022
-
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation. 1991 Oct; 52(4):590-4.
Score: 0.022
-
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc. 1991 Feb; 23(1 Pt 1):14-21.
Score: 0.021
-
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc. 1990 Feb; 22(1):52-6.
Score: 0.020
-
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc. 1990 Feb; 22(1):6-12.
Score: 0.020
-
Overview of FK506 in transplantation. Clin Transpl. 1990; 115-21.
Score: 0.019
-
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl. 2005 Nov; 11(11):1343-52.
Score: 0.015
-
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg. 2005 Apr; 200(4):505-15; quiz A59-61.
Score: 0.014
-
Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc. 2005 Mar; 37(2):923-6.
Score: 0.014
-
Synergistic effect of cold and warm ischemia time on postoperative graft outcome in human liver transplantation. Hepatogastroenterology. 2004 Sep-Oct; 51(59):1413-6.
Score: 0.013
-
Porcine partial liver transplantation: a novel model of the "small-for-size" liver graft. Liver Transpl. 2004 Feb; 10(2):253-63.
Score: 0.013
-
Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant. 2003 Apr; 17(2):77-88.
Score: 0.012
-
Hamster-to-rat bone marrow xenotransplantation and humoral graft vs. host disease. Xenotransplantation. 2001 Aug; 8(3):213-21.
Score: 0.011
-
Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol. 2001 Apr; 158(4):1379-90.
Score: 0.011
-
Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc. 2001 Feb-Mar; 33(1-2):1235-6.
Score: 0.011
-
The long-term efficacy of multivisceral transplantation. Transplant Proc. 2000 Sep; 32(6):1219-20.
Score: 0.010
-
Xenogeneic humoral graft-Vs-host disease following hamster-to-Rat bone marrow transplantation. Transplant Proc. 2000 Aug; 32(5):1036-7.
Score: 0.010
-
Loss of serum bicarbonate after discordant liver xenotransplantation. Transplant Proc. 2000 Aug; 32(5):1110.
Score: 0.010
-
Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. Liver Transpl Surg. 1999 Mar; 5(2):101-6.
Score: 0.009
-
Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. Transplant Proc. 1999 Feb-Mar; 31(1-2):1244.
Score: 0.009
-
Simultaneous pancreas-kidney transplantation at the University of Pittsburgh. Clin Transpl. 1999; 217-21.
Score: 0.009
-
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg. 1998 May; 186(5):512-25; discussion 525-7.
Score: 0.009
-
Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation. 1998 Feb 27; 65(4):499-504.
Score: 0.009
-
Central venulitis in the allograft liver: a clinicopathologic study. Transplantation. 1997 Jul 27; 64(2):252-7.
Score: 0.008
-
Non-lymphoid cancer after liver transplantation. Hepatogastroenterology. 1997 Jul-Aug; 44(16):1172-81.
Score: 0.008
-
Preoperative assessment of risk in liver transplantation: a multivariate analysis in 2376 cases of the UW era. Transplant Proc. 1997 Feb-Mar; 29(1-2):454-5.
Score: 0.008
-
Experimental animal model of graft-versus-host disease (GVHD) after small-bowel transplantation: characteristics of the model and application to developing treatment strategies. Transplant Proc. 1997 Feb-Mar; 29(1-2):700.
Score: 0.008
-
Weaning of immunosuppression in liver transplant recipients. Transplantation. 1997 Jan 27; 63(2):243-9.
Score: 0.008
-
Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc. 1996 Oct; 28(5):2959-65.
Score: 0.008
-
Prolonged survival of hearts obtained from chimeric donors in a mouse to rat xenotransplant model. Transplant Proc. 1996 Apr; 28(2):733-4.
Score: 0.008
-
Xenotransplantation of hamster liver into Gunn rats reserves congenital hyperbilirubinemia. Transplant Proc. 1996 Apr; 28(2):735.
Score: 0.008
-
Small bowel transplantation: current progress and clinical application. Hepatogastroenterology. 1996 Mar-Apr; 43(8):363-76.
Score: 0.007
-
Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. J Clin Invest. 1996 Jan 01; 97(1):217-25.
Score: 0.007
-
Mechanisms of protection from humoral rejection by a xenografted liver. Transplant Proc. 1995 Feb; 27(1):300-2.
Score: 0.007
-
Three years clinical experience with intestinal transplantation. J Am Coll Surg. 1994 Oct; 179(4):385-400.
Score: 0.007
-
Complement and target cells belong to the same species after liver xenografting: protection from hyperacute rejection. Transplant Proc. 1994 Jun; 26(3):1255.
Score: 0.007
-
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc. 1993 Dec; 25(6):3337-44.
Score: 0.006
-
Dendritic cell replacement in long-surviving liver and cardiac xenografts. Transplantation. 1993 Aug; 56(2):482-4.
Score: 0.006
-
Humoral and cellular immunopathology of hepatic and cardiac hamster-into-rat xenograft rejection. Marked stimulation of IgM++bright/IgD+dull splenic B cells. Am J Pathol. 1993 Jul; 143(1):85-98.
Score: 0.006
-
Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. Transplant Proc. 1993 Feb; 25(1 Pt 1):414-5.
Score: 0.006
-
Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors. Transplant Proc. 1993 Feb; 25(1 Pt 1):781-3.
Score: 0.006
-
Nutritional management of intestinal transplant recipients. Transplant Proc. 1993 Feb; 25(1 Pt 2):1200-1.
Score: 0.006
-
Management of intestinal transplantation in humans. Transplant Proc. 1992 Jun; 24(3):1243-4.
Score: 0.006
-
The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. Transplant Proc. 1991 Dec; 23(6):3021-2.
Score: 0.006
-
FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery. 1991 Aug; 110(2):357-63; discussion 363-4.
Score: 0.005
-
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation. 1991 Jul; 52(1):71-7.
Score: 0.005
-
Effects of in vivo treatment with FK506 on natural killer cells in rats. Transplantation. 1991 Apr; 51(4):913-5.
Score: 0.005
-
Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. Transplant Proc. 1991 Feb; 23(1 Pt 2):1108-10.
Score: 0.005
-
Liver transplantation under cyclosporine: a decade of experience. Transplant Proc. 1991 Feb; 23(1 Pt 2):1393-6.
Score: 0.005
-
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc. 1991 Feb; 23(1 Pt 2):1397-402.
Score: 0.005
-
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc. 1991 Feb; 23(1 Pt 2):914-9.
Score: 0.005
-
Use of FK 506 in pediatric patients. Transplant Proc. 1991 Feb; 23(1 Pt 2):924-7.
Score: 0.005
-
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg. 1990 Sep; 212(3):295-305; discussion 306-7.
Score: 0.005
-
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation. 1990 Aug; 50(2):186-9.
Score: 0.005
-
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet. 1990 Mar 17; 335(8690):674.
Score: 0.005
-
Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. Transplant Proc. 1990 Feb; 22(1):106-9.
Score: 0.005
-
FK 506 dosage in human organ transplantation. Transplant Proc. 1990 Feb; 22(1):23-4.
Score: 0.005
-
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc. 1990 Feb; 22(1):25-34.
Score: 0.005
-
The side effects of FK 506 in humans. Transplant Proc. 1990 Feb; 22(1):35-6.
Score: 0.005
-
Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc. 1990 Feb; 22(1):41-3.
Score: 0.005
-
Infections with FK 506 immunosuppression: preliminary results with primary therapy. Transplant Proc. 1990 Feb; 22(1):44-6.
Score: 0.005
-
Assay of FK 506 in plasma. Transplant Proc. 1990 Feb; 22(1):50-1.
Score: 0.005
-
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc. 1990 Feb; 22(1):57-9.
Score: 0.005
-
Studies of the hepatotrophic qualities of FK 506 and CyA. Transplant Proc. 1990 Feb; 22(1):93-5.
Score: 0.005